OBJECTIVES: Right heart failure is a major cause of morbidity and mortality after left ventricular assist device implantation and is still hard to predict. This study investigated the haemodynamic effect of a modified Glenn shunt on induced right ventricular (RV) failure.
INTRODUCTION
There is an increasing number of patients being considered for left ventricular assist device (LVAD) therapy both as bridge to transplant and as destination therapy [1] [2] [3] . Among these patients, a substantial number have some degree of right ventricular (RV) dysfunction preoperatively. Although several risk prediction models have been developed for evaluating which patients are at high risk for RV failure, the clinical problem is somewhat unpredictable and remains partly unsolved [4] [5] [6] . Unfortunately, RV failure is associated with high post-LVAD morbidity and mortality rates [7, 8] . The clinical management for avoiding RV failure pre-and postoperatively mainly focuses on preoperative risk prediction, perioperative echocardiography, volume management, inotropes and pulmonary vasodilator support and avoidance of bleeding and transfusion. However, once non-reversible RV failure occurs in the LVAD setting, the only reliable option is the placement of a right ventricular assist device. In these patients, the reduction of central venous pressures (CVPs) to avoid venous congestion and thereby relieve or prevent end-organ failure is essential to make heart transplantation a future option.
In children with congenital heart defects, RV dysfunction after biventricular repair has been managed with a bidirectional Glenn shunt, a shunt between the superior vena cava (SVC) to the right pulmonary artery (PA) [9, 10] . This approach could be of use for patients with acute perioperative RV failure and low pulmonary vascular resistance, but needs to be systematically evaluated.
This study investigated whether partial surgical exclusion of the RV overload with a modified Glenn shunt during an acute RV failure improved haemodynamics and reversed venous congestion in an experimental model.
MATERIALS AND METHODS
The study was approved by the Uppsala Ethical Committee on Laboratory of Animal Research and all animals received humane care in compliance with the European Convention on Animal Care.
Anaesthesia
The study comprised 13 piglets of Swedish country breed with a mean weight of 38.5 kg (33.5-54). General anaesthesia was induced by a subcutaneous injection of xylazine (Rompun ® 2.2 mg/kg, Bayer A/S, Lyngby, Denmark) and tiletamine/zolazepam (Zoletil 100 ® 6.0 mg/kg, Virbac S.A., Carros Cedex, France). This was maintained by infusion of a buffered glucose solution carrier (Rehydrex ® with glucose 25 mg/ml, Fresenius Kabi AB, Uppsala, Sweden) with ketamine 30 mg/kg/h (Ketaminol Vet ® 100 mg/ml, Intervet AB, Stockholm, Sweden); fentanyl 0.04 mg/kg/h (Fentanyl 50 µg/ml, B Braun Medical AB, Danderyd, Sweden); midazolam 0.1 mg/kg/h (Midazolam Hameln 1 mg/ml, AlgolPharma AB, Kista, Sweden) and pancuronium bromide 0.3 mg/kg/h (Pavulon ® 2 mg/ ml, ScheringPlough AB, Stockholm, Sweden).
Body temperature was controlled with a heating pad, aiming for a core temperature of 37°C.
The piglets were intubated and mechanically ventilated with 40% oxygen via a Siemens Servo-i ventilator (MaquetGmbh & Co. KG, Rastatt, Germany). Volume-controlled ventilation aimed at an arterial pCO 2 within the range of 5.0-5.5 kPa and a positive end-expiratory pressure (PEEP) of 5 cm was applied. The urine bladder was catheterized with a silicone catheter.
A catheter was inserted through the right external jugular vein (BD Careflow 17G) for monitoring central venous pressure, blood sampling and drug administration. The left femoral vein was catheterized for intravenous administration of complementary anaesthetic drugs and fluids. A catheter was inserted into the left femoral artery for continuous monitoring of the arterial blood pressure with a pressure transducer (BD Careflow 20G; Becton Dickinson AB, Stockholm, Sweden).
Surgical preparation
Median sternotomy was performed. The azygos and hemiazygos veins were ligated. A modified Glenn shunt was created by connecting the SVC with the main PA with a 12-mm Dacron graft (Gelsoft ™ , Vascutek, Inchinnan, Scotland, UK) with partial clamps on the vessels. The graft was anastomosed with a running suture. Pressure transducer catheters were surgically placed in the right atrium (RA), right ventricle (RV), left atrium (LA) and PA. The catheters were secured with sutures and connected to a monitoring system (Dräger Infinity Delta). The animals were heparinized with a single dose of 7500 IU at baseline and then 5000 IU every 2 h throughout the experiment. An ultrasonic flow probe (VeriQ Perivascular 12 mm, MediStim ASA, Oslo, Norway) was positioned around the modified Glenn shunt. The modified Glenn shunt was closed with a vascular clamp until put in use. When the modified Glenn shunt was put in use, the vascular clamp was removed from the shunt and the SVC was clamped below the shunt, directing all blood from the SVC to the main PA through the modified Glenn shunt (Fig. 1) .
Right ventricular heart failure
The model of isolated RV failure was created by subsequent ligation of 4-6 acute marginal branches of the right coronary artery and branches to the right ventricle from the left main coronary artery. RV branches supplying the interventricular septum (i.e. posterior descending artery) or the inferior surface of the left ventricle were avoided to prevent injury to the LV wall or septum. RV failure was considered present at RA pressure ≥20 mmHg. The RV was further challenged with a volume overload of 2000 ml Hesra (Baxter Medical AB, Kista, Sweden).
Measurements
Standard lead II electrocardiography (ECG), systemic arterial blood pressure, RA pressure, RV pressure, LA pressure and PA blood pressure were monitored continuously and recorded. Cardiac output (CO) was measured through the thermodilution technique during baseline and RV failure. CO during RV failure and shunt was calculated using VO 2 (oxygen uptake) during RV failure according to: VO 2 = CO × [CaO 2 (arterial oxygen content) − CVO 2 (venous oxygen content)]. Arterial blood gases, venous blood gases and haematocrit were continuously monitored with ABL 500 Radiometer (Medical ApS, Bronshoj, Denmark).
Measurements were taken at the following three time periods: (1) baseline, (2) RV failure and closed modified Glenn shunt and (3) RV failure and open modified Glenn shunt.
The baseline values were taken 30 min after the animals were prepared. All RV failure data were collected after 20 min of stabilization. Data from the period with the shunt in use were collected after 20 min of stabilization. For analysis of microarray and genetic expression, myocardial biopsies were taken with a middle needle from the free wall of the RV at sites of coronary branch ligation at the end of the period of heart failure.
At the end of the experiment, the animals were euthanized by an intraventricular injection of potassium chloride. Autopsies were performed and the hearts were excised and shunt opened for inspection. 
Microarray
Analysis of gene expression was performed to ascertain the expression of previously known heart failure genes and thereby validate established RV failure. The myocardial biopsies were stored at −80°C until the use and homogenized using a mechanical tissue homogenizer (Polytron, Kinomatica AG Lucerne, Switzerland). The RNA was extracted by TRIZOL © reagent and protocol (Life Technologies™). For samples with an A260/ A280-ratio >1.7, the concentration of the extracted RNA was measured by spectrophotometry (Nanodrop ND-1000 spectrophotometer, Saveen Werner). The RNA was purified with RNeasy columns (Qiagen N.V., Netherlands) and the integrity of the RNA was evaluated through microcapillary electrophoresis (Agilent BioAnalyzer) measuring 18S and 28S rRNA, the RNA integrity number (RIN) value >7 for all samples.
RNA from each sample was used to prepare biotinylated fragmented cRNA according to the GeneChip® 3 0 IVT Express Kit Manual (PN 702646 Rev1, Affymetrix Inc., Santa Clara, CA, USA). Affymetrix GeneChip® expression arrays (Porcine Genome Array) were hybridized for 16 h in a 45°C incubator, rotated at 60 rpm. According to the GeneChip® Expression Wash, Stain and Scan Manual (PN 702731 Rev2, Affymetrix Inc.), the arrays were then washed and stained with the Fluidics Station 450 and finally scanned with the GeneChip® Scanner 3000 7G.
Data analysis and statistics
The value for each pig was the mean of all measurements for each period. Data are expressed as medians with 95% confidence interval (CI) in brackets. Due to small sample size, nonparametric statistical analyses were used. Differences between the three periods, baseline, RV failure and RV failure + shunt were compared between groups using the Wilcoxon matched pairs signed-rank test. The CIs were calculated and the 95% CIs are presented in brackets. All P-values <0.05 were considered statistically significant in all tests. Statistical calculations were performed with the statistical package 12.0 (SPSS, Chicago, IL, USA). Partek Genomic Suite software (Partek Inc., St Louis, MO, USA) was used for statistical analysis of the microarray data, and two-way analysis of variance was carried out to test differences from baseline.
RESULTS
Thirteen pigs were included in the study. Two pigs were excluded as they died during the experiment: one during surgical preparation and the other due to persistent ventricular fibrillation during the ligation of coronary arteries. The 11 surviving pigs constituted the study group. Fig. 3 ).
Right ventricular failure and use of the modified Glenn shunt
The median flow in the shunt was 681 ml (Table 1 ). There was a reduction in RA pressure from 20.3 (19.6-21.1) to 13.4 mmHg (12.7-14.0), P = 0.001, when the shunt was in use. There was also an increase in CO during the use of the shunt from 2.3 (2.0-2.6) to 2.9 l/min (2.5-3.3), P < 0.01. There was also a decrease in mean RV pressure from 18.1 (16.4-20.1) to 13.6 (13.5-14.2), P = 0.001, (Fig. 2) . As shown in Table 1 , RV systolic pressure and RV diastolic pressure decreased with the shunt in use, P < 0.01. In addition, the RVSV decreased from 36.7 (29.3-44.2) to 27.3 ml (20.3-34.3) as depicted in Table 1 .
Moreover, MAP increased from 55.9 (52.6-59.8) to 67.5 mmHg (65.9-75.5), P = 0.001 (Fig. 3) . The systemic venous oxygen saturation (SVO 2 ) increased with the use of the shunt from 32.2 (26.6-37.7) to 49.1% (45.1-56.3), P = 0.001, compared with the period of RV failure without the shunt (Fig. 4) .
In addition, during use of the shunt, PA pressure decreased from 22.1 (20.2-22.6) to 17.1 mmHg (15.6-17.4), P = 0.001, (Table 1) . There was no difference in LA pressure at RV failure with the use of the shunt of 14.5 mmHg (13.9-16.4) compared with without the use of the shunt of 16.1 mmHg (13.6-17.2).
The analysis of blood gases during the experiment is presented in Table 2 . During the period of RV failure, the haemoglobin (Hb) level decreased to 27% lower than the baseline value: the median Hb level was 60 g/l during the use of the shunt compared with 82 g/l at baseline as shown in Table 2 . The levels of pO 2 were consistent throughout the experiment.
Microarray
Several genes previously associated with heart failure were upregulated during the period of RV failure. The genes that were upregulated with a fold change ≥1.44 (the 20 most upregulated) from baseline to RV failure are presented in Table 3 . The three genes with the highest fold change were Heat shock 27 kDa protein 2 at 2.23, Natriuretic peptide A at 2.15 and Forkhead box J3 (FOXJ3) at 2.06. Other genes previously associated with heart failure that were upregulated during the episode of RV failure included Vinculin at 1.89, Nebulette at 1.61 and Histone deacetylase 8 at 1.50.
A complete gene list is published at www.genome.ucsc.edu/.
COMMENT
In this study, the modified Glenn shunt improved the haemodynamic profile of acute RV failure by decreasing the right atrial pressure, increasing MAP and CO and increasing SVO 2 . The achievement of right heart failure in this experimental model was confirmed by upregulation of genes previously associated with heart failure. There is a lack of a uniform definition of clinical RV failure in LVAD candidates [4-8, 11, 12] . This is to compare with most 
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P. Vikholm et al. / European Journal of Cardio-Thoracic Surgeryexperimental studies regarding heart failure where there often is a lack of a solid definition of heart failure in the experimental protocol. Therefore, in this experimental model of acute heart failure, it was important to ascertain that the selected definition of heart failure actually reflected a stage of established RV failure. Consequently, we combined the haemodynamic definition of RV failure (RA ≥ 20 mmHg) with an analysis of gene expression and found that RV failure was established to the extent that was considered satisfactory. We believe that a reliable gene expression was produced in this model since the degree and the mechanism of RV failure were relatively homogenous and that established RV failure (RA ≥ 20 mmHg) was validated.
RV failure is a major contributor of significant morbidity and mortality after LVAD placement [4-8, 11, 12] . In these patients, RV failure results in decreased contractility and unability of the RV to produce adequate filling of the LV assist due to dilation, distension and ischaemia. The treatment of this clinical problem includes three main focuses: ensurance of right coronary perfusion by adequate blood pressure, volume unloading of the RV and limiting pulmonary vasoconstriction. The unloading of the RV is crucial to avoid distension and thereby backward failure. Once severe RV failure is present, end-stage therapies include RV assist devices or extra corporeal membrane oxygenation. Unfortunately, an increased number of cannulae and pumps will also increase the risk of infection, bleeding and thrombotic events [13, 14] . From this view, a modified Glenn shunt might be a possible option since it will act to both unload the RV and also sustain filling of the LV assist.
A reduction of CVPs is important to restore and prevent end-organ failure and traditionally, a decrease in renal function in advanced decompensated heart failure has been attributed to hypoperfusion of the kidney due to impaired CO [15] . Today, there are numerous reports indicating that the strongest haemodynamic determinant of worsening renal function in heart failure is the presence of 'backward failure' and venous congestion as measured by elevated CVP [16, 17] . Some borderline patients, with moderate RV failure after LVAD implant may require advanced treatment for RV failure such as prolonged inotropes and intensive care, which interfere with their clinical improvement. For these patients, a sufficient reduction of CVP is essential to restore and prevent end-organ failure, to improve long-term prognosis and to enable future heart transplantation. The current study suggests that this can be achieved with the Glenn shunt, which decreased mean RA pressure (surrogate for CVP) from 20.3 to 13.4 mmHg. In addition, others have shown that a secondary effect of RV volume exclusion is a partial reversal of the left ventricular dysfunction that occurs during RV failure [18] . However, the modified Glenn shunt is only a possible solution in patients with low pulmonary vascular resistance and LV end-diastolic pressure.
In addition, the long-term efficacy and consequences of this model of RV function are unknown. For example, in Fontan candidates, a possible long-term consequence is increased pulmonary vascular resistance due to pulmonary congestion and in turn increased filling pressures in the RV leading to worsening of RV function. However, the major difference between the Fontan patients and the LVAD patients is the LVAD itself, which actively relieves the pulmonary vascular bed from congestion. The modified Glenn connection frequently used in congenital heart defects in children has not been shown to further worsen RV failure. Our suggestion is that the concept of partly bypassing the RV could be useful in LV assist patients at least temporarily to reduce CVPs while awaiting heart transplantation.
Furthermore, there was a decline in haemoglobin throughout the experiment. Regardless of this decline, there was an increase in SVO 2 with the use of the Glenn shunt. As blood oxygen is dependent on haemoglobin concentration, these observations indicated improved oxygen delivery with the use of the shunt. Naturally, blood oxygen concentration and venous saturation could be further improved in clinical practice where falls in haemoglobin are normally transfused.
There are two previous studies on the use of a modified Glenn shunt in settings of induced RV failure. However, niether of them has actually studied the reversal of the impaired haemodynamics as such, which we believe motivates our study. Danton et al. [19] demonstrate, in eight pigs, that the dilation of RV in ischaemic RV failure decreases left ventricular contractility and relaxation. Although the institution of the shunt improves left ventricular impairment, there is no improvement in the contractility of the RV, evaluated with pressure-volume loops. In that study, the shunt improved right ventricular end-diastolic pressure. However, global haemodynamic improvements such as MAP, CVPs or SVO 2 were not analysed.
In another study, on 14 randomized dogs, the shunt improved haemodynamic performance measured as RV pressure, MAP and PA flow in an experimental setting with LVAD and induced ventricular fibrillation [20] . However, RA pressure was not measured and replication in a clinical setting is limited as the model used the induction of ventricular fibrillation to create a state of biventricular failure. Finally, these studies provide scarce information of the definition of RV failure.
Clinical implications
There are some possible clinical gains with the modified Glenn concept in LVAD candidates. First, the reduction of CVPs might help to avoid further deterioration of or restore end-organ function although the long-term consequences are unknown. Secondly, the unloading of the RV reduces dilation and thereby hopefully postponing of the stepwise RV deterioration that occurs in LVAD patients on destination therapy; although this will be palliative rather than curative in nature.
LIMITATIONS
There are several limitations of our study, including that the long-term patency of the results was not secured in this model of acute heart failure. Also, in this model of ischaemic RV failure, the LV wall or septum could possibly have been affected when ligation of coronary arteries was performed. However, this ischaemic model has been frequently used [19] and branches supplying the LV were avoided. Although there might some affection of the LV, we believe that the haemodynamics of the RV can still be assessed. In addition, the open chest model did not allow echocardiography of the heart for assessment of changes in RV geometry during the use of the shunt. This aspect can be addressed with analyses of pressure-volume loops in future studies.
Moreover, there was a pressure difference of 9 mmHg between the SVC and the PA when the shunt was in use, which could possibly indicate a narrowing of the graft caused by the flow probe. This dilemma can hopefully be avoided when a true modified Glenn shunt (the true SVC dislocated and connected to PA) and not a graft can be used. There was no obstruction caused by thrombus formation since all shunts were inspected and the end of the experiment.
Furthermore, numerous patients with chronic congestive heart failure will have increased pulmonary vascular resistance, which will disqualify the concept of the Glenn shunt. Finally, the reproducibility of the genetic expression needs to be confirmed and refined with another genetic method such as PCR.
CONCLUSIONS
We established a reliable experimental model in which the degree of RV failure was secured with expression of genes previously associated with heart failure. A modified Glenn shunt improved haemodynamics with reduced central venous pressure, increased MAP, CO and systemic venous saturation during RV failure. Our data imply that RV overload and thereby venous congestion during RV failure can be avoided with this concept.
